Apriori Bio, a Flagship Pioneering company focused on developing superior prospective vaccines, today announced an extension of its grant from CEPI to continue advancing Octavia™, the company’s biology-enabled AI platform for the design of variant-resilient vaccines. The extension of the collaboration will enable Apriori to build on strong early progress by completing planned in vivo experimental work to further demonstrate Octavia’s iterative antigen design capabilities, using influenza A (H3) as a model.

“CEPI’s continued support speaks to the strength of Octavia to completely transform how vaccine antigens are designed,” said Craig Williams, MBA, Chief Executive Officer of Apriori Bio and CEO-Partner at Flagship Pioneering. “As the only company pairing robust predictive intelligence with full scale experimental validation, we’re showing how we can reliably generate higher-performing vaccine candidates and can serve as a trusted partner for addressing both current and emerging seasonal and pandemic viral threats. We look forward to continuing our work with CEPI on these globally important advancements.”

The extension underscores Apriori’s potential to accelerate the development of more effective, longer-lasting vaccines. Octavia reinvents vaccine design by predicting viral evolution and designing antigens that program the ideal immune response.

Apriori Receives Grant Extension from CEPI to Further Advance Octavia™ Platform